I
Implicit Bioscience
Implicit Bioscience Ltd operates as a clinical-stage drug development company
About Implicit Bioscience
Implicit Bioscience is a biotechnology company focused on developing innovative therapies that target immune responses to treat serious diseases. Operating primarily in the healthcare and pharmaceutical markets, the company serves clinicians and patients dealing with heart diseases, respiratory conditions, and other immune-related disorders. Its lead product, IC14, is a novel monoclonal antibody designed to block CD14, a key regulator of the immune response, showing potential in treating conditions such as COVID-19 and arrhythmogenic cardiomyopathy (ACM). The company generates revenue through clinical trials, partnerships, and potential future sales of its therapeutic products.
Source: Dealroom company dataAt a glance
- Founded
- 2004
- Headquarters
- Seattle, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innovation Connections
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Implicit Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Implicit Bioscience on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.